Paragon Associates & Paragon Associates Ii Joint Venture Abb Vie Inc. Transaction History

Paragon Associates & Paragon Associates Ii Joint Venture

$54 Million
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$85.91 - $100.83 $5.15 Million - $6.05 Million	-60,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $4.4 Million - $5.89 Million	60,000 New	60,000 $5.89 Million
Q1 2020 May 15, 2020	SELL	$64.5 - $97.79 $9.68 Million - $14.7 Million	-150,000 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$62.98 - $75.72 $8.82 Million - $10.6 Million	140,000 Added 1400.0%	150,000 $11.4 Million
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $657,000 - $839,800	10,000 New	10,000 $727,000

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Paragon Associates & Paragon Associates Ii Joint Venture, based on Form 13F filings with the SEC.

News

Stay updated on Paragon Associates & Paragon Associates Ii Joint Venture with notifications on news.

Account